國芯科技(688262.SH):公司汽車電子芯片已陸續進入比亞迪等眾多汽車整機廠商
格隆匯9月5日丨國芯科技(688262.SH)近期在接待機構投資者調研時表示,公司汽車電子芯片已陸續進入比亞迪、奇瑞、吉利、上汽、長安、長城、一汽、東風、小鵬等眾多汽車整機廠商,在20餘款自主及合資品牌汽車上實現批量應用。截至2023年6月30日,已量產的汽車電子項目數(個)達到13個,新開發的汽車電子項目數(個)達到56個。接下來,公司將繼續集中力量做好新項目的開發工作,着力攻堅頭部重點客户、重點項目,儘可能實現項目的快速量產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.